Cited by 521Lipoproteins and Cardiovascular HealthGenetic Associations and EpidemiologyAtherosclerosis and Cardiovascular Diseases

The DOI matches its Crossref record; 204 of the 204 references it cites were found in a registry or an index.

Lipoprotein(a): resurrected by genetics

Open access

Kronenberg, F., Utermann, G.·2013·Journal of Internal Medicine

DOI 10.1111/j.1365-2796.2012.02592.x

Open this paper in CoChat — free account Open PDF

Abstract

Plasma lipoprotein(a) [L p(a)] is a quantitative genetic trait with a very broad and skewed distribution, which is largely controlled by genetic variants at the LPA locus on chromosome 6q27. Based on genetic evidence provided by studies conducted over the last two decades, L p(a) is currently considered to be the strongest genetic risk factor for coronary heart disease (CHD). The copy number variation of kringle IV in the LPA gene has been strongly associated with both L p(a) levels in plasma and risk of CHD, thereby fulfilling the main criterion for causality in a M endelian randomization approach. Alleles with a low kringle IV copy number that together have a population frequency of 25–35% are associated with a doubling of the relative risk for outcomes, which is exceptional in the field of complex genetic phenotypes. The recently identified binding of oxidized phospholipids to L p(a) is considered as one of the possible mechanisms that may explain the pathogenicity of L p(a). Drugs that have been shown to lower L p(a) have pleiotropic effects on other CHD risk factors, and an improvement of cardiovascular endpoints is up to now lacking. However, it has been established in a proof of principle study that lowering of very high L p(a) by apheresis in high‐risk patients with already maximally reduced low‐density lipoprotein cholesterol levels can dramatically reduce major coronary events.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1111/j.1365-2796.2012.02592.x

Cites

204 of 204 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A Receptor-Mediated Pathway for Cholesterol Homeostasis
Brown, M. S., & Goldstein, J. L. (1986) · Science · doi:10.1126/science.3513311 · Cited by 5,703
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487
Self-citation
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
cDNA sequence of human apolipoprotein(a) is homologous to plasminogen
McLean, J. W., Tomlinson, J. E., Kuang, W.-J., Eaton, D. L., Chen, E. Y., Fless, G. M., Scanu, A. M., & Lawn, R. M. (1987) · Nature · doi:10.1038/330132a0 · Cited by 1,886
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease
Cardiogenics, Schunkert, H., the CARDIoGRAM Consortium, König, I. R., Kathiresan, S., Reilly, M. P., Assimes, T. L., Holm, H., Preuss, M., Stewart, A. F. R., et al. (2011) · Nature Genetics · doi:10.1038/ng.784 · Cited by 1,866
Lipoprotein(a) as a cardiovascular risk factor: current status
Nordestgaard, B. G., Chapman, M. J., Ray, K., Borén, J., Andreotti, F., Watts, G. F., Ginsberg, H., Amarenco, P., Catapano, A., Descamps, O. S., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq386 · Cited by 1,807
Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality
(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902604 · Cited by 1,671
Inflammation enhances cardiovascular risk and mortality in hemodialysis patients
Zimmermann, J., Herrlinger, S., Pruy, A., Metzger, T., & Wanner, C. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00273.x · Cited by 1,531
A NEW SERUM TYPE SYSTEM IN MAN—THE Lp SYSTEM
Berg, K. (1963) · Acta Pathologica Microbiologica Scandinavica · doi:10.1111/j.1699-0463.1963.tb01808.x · Cited by 1,383

Show all 203 references

Research works printed but not linked: 2

Utermann G, 2000, The Metabolic & Molecular Bases of Inherited Disease, 2753
10.1210/jc.81.7.2633 · DOI

Sorted by citations

Items 401–500 of 521

Plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) is associated with Lp(a) in type 2 diabetic patients
Nekaies, Y., Baudin, B., Sakly, M., & Attia, N. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.04.356 · Cited by 2
The Association of Lipoprotein(a), Apolipoprotein(a) Phenotypes and Autoantibodies to Lipoprotein(a) With Lower Extremity Artery Disease
Tmoyan, N. A., Afanasieva, O. I., Александровна, К. Е., Afanasieva, M. I., Андреевна, Р. О., Владиславович, Е. М., & Pokrovsky, S. N. (2018) · Kardiologiia · doi:10.18087/cardio.2018.12.10176 · Cited by 2
Role of Lp(a) in patients with erectile dysfunction undergoing angioplasty for symptomatic pelvic artery disease
Kalka, C., Lippik, L., Wenzel, F., Hoppe, H., Keo, H. H., Heiß, C., & Diehm, N. (2023) · VASA · doi:10.1024/0301-1526/a001072 · Cited by 2
Lipoprotein apheresis in the management of severe hypercholesterolemia and hyperlipoproteinemia(a)—The Portuguese experience
Ferreira, L., Palma, I., Bacelar, C., Queirós, J. A., Madureira, A., Oliveira, J. C., Ramos, M. H., & Cardoso, H. (2018) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2018.08.004 · Cited by 2
Pathogenesis of atherosclerosis: lipid metabolism
Wiklund, O., & Borén, J. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780198755777.003.0011 · Cited by 2
Lipoprotein(a) Should Be Measured in All Individuals Suspected of Having Familial Hypercholesterolemia
Langsted, A., & Nordestgaard, B. G. (2019) · Clinical Chemistry · doi:10.1373/clinchem.2019.308650 · Cited by 2
LDL-C: An Important Independent Risk Factor for New-Onset Heart Block in Patients with Severe Aortic Stenosis and Heart Failure after TAVR
Dong, M., Wang, L., Tse, G., Dai, T., Lv, T., Zhang, N., Wang, L., Xiao, Z., Chen, T., Liu, T., et al. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2408243 · Cited by 1
Clinical-epidemiological analysis of patients with elevated lipoprotein A in a third level hospital
de Prada, M. G., Segovia, R. C., Martínez, M. D. C., Hidalgo, N. V., López, M. B. S., & Echevarría, A. B. (2024) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2024.05.002 · Cited by 1
Atherosclerosis
Mayer, F., Innerhofer, R., Köller, T., & Binder, C. J. (2024) · Learning materials in biosciences · doi:10.1007/978-3-031-64591-4_10 · Cited by 1
Lipoproteina(a) e rischio cardiovascolare: una roadmap per la gestione del paziente. Documento congiunto della Società Italiana per lo studio dell'Aterosclerosi (SISA), della Società Italiana di Cardiologia (SIC), della Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) e di SIBioC
Catapano, A. L., Filardi, P. P., Oliva, F. G., Agnello, L., Baragetti, A., Berteotti, M., Bilato, C., Calabrò, P., Cesaro, A., Gori, A. M., et al. (2025) · Biochimica Clinica · doi:10.23736/s0393-0564.25.00077-9 · Cited by 1
Assessment of the Utilization of Lipoprotein (a) and its Relationship with Cardiovascular Outcomes: A Retrospective Cohort Study from a Public Hospital in New York City
Maliha, M., Nazarenko, N., Nagraj, S., Satish, V., Kharawala, A., Borkowski, P., Garg, V., Saralidze, T., Karamanis, D., & Palaiodimos, L. (2025) · Heart Views · doi:10.4103/heartviews.heartviews_138_24 · Cited by 1
Multiplexed Quantification of First-Trimester Serum Biomarkers in Healthy Pregnancy
Starodubtseva, N. L., Tokareva, A., Kononikhin, A. S., Brzhozovskiy, A. G., Bugrova, A. E., Kukaev, E., Poluektova, A., Евгеньевич, Ф. В., Николаев, Е. Н., & Sukhikh, G. T. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167970 · Cited by 1
Lipoprotein(a) and cardiovascular risk: A roadmap for patient management
Catapano, A. L., Filardi, P. P., Oliva, F. G., Agnello, L., Baragetti, A., Berteotti, M., Bilato, C., Calabrò, P., Cesaro, A., Gori, A. M., et al. (2025) · European Atherosclerosis Journal · doi:10.56095/eaj.v4i3.113 · Cited by 1
A narrative review of impacts of apolipoproteins on atherosclerotic coronary plaques
Fukase, T., & Dohi, T. (2026) · npj Cardiovascular Health · doi:10.1038/s44325-026-00104-x · Cited by 2
Circulating lipoprotein(a) levels and steatotic liver disease related to metabolic dysfunction in adults: an updated systematic review and meta-analysis
Mustafa, A., Dallaway, A., Lagojda, L., Kite, C., Abdelhameed, F., Chatha, K. K., Suresh, A., Randeva, H. S., & Kyrou, I. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1778393 · Cited by 1
Expert consensus on Lipoprotein(a) in the Gulf countries: Navigating cardiovascular risk and therapeutic advances
Almahmeed, W. A., Sabbour, H. M., Shantouf, R. S., Aljaberi, A. K., Tamimi, H. E., Lootah, F. B., Sayed, N. A., Ali, J. A., Akbar, M. A. J., Shehab, A., et al. (2026) · Atherosclerosis Plus · doi:10.1016/j.athplu.2026.100569 · Cited by 1
Mendelian Randomization Reveals Interleukin-6 Receptor-Lipoprotein(a) Interplay With Independent Cardiovascular Risk Reductions
Kheirkhah, A., Maio, S. D., Coassin, S., Schönherr, S., Lamina, C., Forer, L., Kronenberg, F., & Schachtl‐Riess, J. F. (2026) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2026.101564 · Cited by 2
Self-citation
Update on Investigation and Management of Dyslipidaemias and Cardiovascular Disease Risk
Antwi, K., Luvai, A., Downie, P., Ghani, A., Maple, M., & Mbagaya, W. (2026) · British Journal of Hospital Medicine · doi:10.31083/bjhm54141 · Cited by 1
Genetically determined very low lipoprotein(a) is not associated with type 2 diabetes and glycemic traits
Lee, M. P., Baca, P., Rivas, F., Zhang, A., Alegre-Díaz, J., Berumen-Campos, J., Kuri-Morales, P., North, K. E., Rodriguez, C. J., Stürmer, T., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101716 · Cited by 1
Biologics for cardiovascular diseases: from bench to bedside
Sun, X., Wang, X., Jia, R., Tang, J., Zeng, X. Y., Zhao, F., Zeng, F., Huang, N., Li, J., & Cui, K. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02673-w · Cited by 2
Lipoprotein(a): when to measure, how to treat?
Chennamsetty, I., Scharnagl, H., Kleber, M. E., März, W., & Kostner, G. M. (2015) · Journal of Laboratory Medicine · doi:10.1515/labmed-2015-0095 · Cited by 1
What does the future hold for cholesteryl ester transfer protein inhibition?
Arsenault, B. J., Boyer, M., & Kastelein, J. J. P. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000248 · Cited by 1
Lipoprotein(a) – es wird Zeit, das Dornröschen wach zu küssen
Kronenberg, F. (2017) · Praxis · doi:10.1024/1661-8157/a002761 · Cited by 1
Self-citation
Lipoprotein(a)—It Is Risky, but What Do We Do About It?
Després, A.-A., & Arsenault, B. J. (2018) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-018-0592-7 · Cited by 1
Genetic Disorders of Lipoprotein Metabolism
Brown, A. S., Dababneh, E. G., Chaus, A. M., Chyzhyk, V., Marinescu, V., & Pyslar, N. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_3 · Cited by 1
Lipoprotein(a)
Enkhmaa, B., Anuurad, E., Zhang, W., & Berglund, L. (2015) · Contemporary Endocrinology · doi:10.1007/978-1-60761-424-1_3 · Cited by 1
A Polynesian-specific SLC22A3 variant associates with low plasma lipoprotein(a) concentrations independent of apo(a) isoform size in males
Wang, Q., McCormick, S. P. A., Leask, M., Watson, H., O'Sullivan, C., Krebs, J. D., Hall, R. M., Whitfield, P., Merry, T. L., Murphy, R., et al. (2024) · Bioscience Reports · doi:10.1042/bsr20240403 · Cited by 1
Six genetic variants are associated with cardiovascular disease independently from canonical risk factors: a new method to refine GWAS results based on the UKBiobank phenotype database
Noto, D., Gagliardo, C. M., Spina, R., Giammanco, A., Ciaccio, M., Cefalu, A. B., & Averna, M. R. (2024) · Molecular Genetics and Genomics · doi:10.1007/s00438-024-02202-w · Cited by 1
Impact of hyperlipoproteinemia(a) on the diagnosis of familial hypercholesterolemia and cardiovascular risk assessment
Муратович, Н. А., Чубыкина, У. В., Зафираки, В. К., & Владиславович, Е. М. (2025) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2025-3106 · Cited by 1
Cholesterol in Atherosclerosis and Cardiovascular Disease: The Role of Specific Dietary and Lifestyle Patterns
Τσούπρας, Α., Lordan, R., & Zabetakis, I. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813792-5.00005-7 · Cited by 1
Pharmacists’ Utilization of Non-HDL-C Levels in Managing Patients With Lipid Disorders
Plakogiannis, R., Saseen, J. J., & Stefanidis, A. (2020) · Hospital Pharmacy · doi:10.1177/0018578720910380 · Cited by 1
Lipoprotein(a) as risk factor for ischemic stroke
Lacková, A., & Kozárová, M. (2021) · Neurologie pro praxi · doi:10.36290/neu.2020.087 · Cited by 1
Exposure to Low Lipoprotein(a) Levels
Arsenault, B. J. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.06.083 · Cited by 1
Proteomic profiling of IDH-wildtype Glioblastoma Tissue and Serum uncovers prognostic Subtypes and Marker CandidatesPreprint
Werner, T., Schäfer, A., Hennes, M., Cosenza‐Contreras, M., Espadas, G., Sabidó, E., Cook, L., Pagenstecher, A., Pinter, N., Feilen, T., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.29.582688 · Cited by 1
Editorial: Impact of elevated lipoprotein(a) on epicardial coronary flow conductance and endoluminal atherosclerotic disease distribution
Waksman, O., & García‐García, H. M. (2025) · Cardiovascular revascularization medicine · doi:10.1016/j.carrev.2025.11.004 · Cited by 1
Analysis of Lipoprotein(a) Receptors: Roles in Catabolism and Pericellular Plasminogen Activation
Romagnuolo, R. (2014)
Lipoprotein(a) — A Hallmark in Atherosclerosis and Cardiovascular Diseases
Chennamsetty, I., & Kostner, G. M. (2015) · InTech eBooks · doi:10.5772/61078
Lipoprotein(a): wann messen, wie behandeln?
Chennamsetty, I., Scharnagl, H., Kleber, M. E., März, W., & Kostner, G. M. (2015) · Journal of Laboratory Medicine · doi:10.1515/labmed-2015-0002
Srce i krvni Sudovi
Beleslin, B., Deljanin, M., Kanjuh, V., Parapid, B. J., Giga, V. L., Prostran, M. S., Angelkov, L., Balinovac, J., Bikicki, M., Ambrosio, G., et al. (2013)
The Changes of Serum Lipoprotein(a) and Plasminogen Activator Inhibitor-1 in Primary Nephrotic Syndrome
Lv, Z.-Z. (2015) · International Journal of Sciences · doi:10.18483/ijsci.864
Original Article Hypoascorbemia induces atherosclerosis and vascular deposition of lipoprotein(a) in transgenic mice
Cha, J., Niedzwiecki, A., & Rath, M. (2015)
Genetic Polymorphisms, Plasma Levels of Lipoprotein (A) and its Possible Links with Degenerative Aortic Stenosis
Tomova, V. D., Rashev, T. R., & Atanasova, M. (2016) · Journal of Biomedical and Clinical Research · doi:10.1515/jbcr-2016-0009
A Potential Role for Sortilin in Lp(a) and Apo(a) Metabolism
Gemin, M. (2017) · Scholarship at UWindsor (University of Windsor)
Kommentar zu den neuen Leitlinien (2016) der European Society of Cardiology und European Atherosclerosis Society zur Diagnostik und Therapie der Dyslipidämien
Landmesser, U., Gohlke, H., Hambrecht, R., Kelm, M., Laufs, U., & Marx, N. (2017) · Der Kardiologe · doi:10.1007/s12181-017-0166-9
Screening for and Optimal Management of Small Abdominal Aortic Aneurysms: The Quest Continues
Paraskevas, K. I., Eckstein, H., Nicolaides, A. N., & Geroulakos, G. (2020) · Current Vascular Pharmacology · doi:10.2174/1570161118999191126145824
Lipoprotein (a): Principles from Bench to Bedside
Koschinsky, M. L., & Boffa, M. B. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_19
Genetic and lifestyle risks of cardiovascular disease
Said, M. A. (2021) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.157192207
Lipoprotein (a) in Youth
McNeal, C. J., & Peterson, A. L. H. (2020)
Juventud y salud cardiovascular: ¿Qué factores de riesgo debemos tener en cuenta para intervenir?
Lozada-Martínez, I., & Bolaño-Romero, M. (2021) · Ciencia e Innovación en Salud · doi:10.17081/innosa.117
Vloga lipoproteina (a) v patogenezi ishemične bolezni srca, degenerativne aortne stenoze in srčnega popuščanja
Zavrtanik, M., Likozar, A. R., & Šebeštjen, M. (2021) · Slovenian Medical Journal · doi:10.6016/zdravvestn.3057
Relationships Between Serum Lipoprotein (a) And Sarcopenia In ElderlyPreprint
Xu, L., Zhou, L., Xiao, Q., Chen, J., Luo, C., Lyu, Q., Zhao, Y., Sun, Y., Zhou, T., & Zhao, K. (2022) · Research Square · doi:10.21203/rs.3.rs-1151264/v1
Lipid-Lowering Drugs
Rye, K., & Barter, P. J. (2021) · Springer eBooks · doi:10.1007/978-3-030-57401-7_6075
Lipid-Lowering Drugs
Rye, K., & Barter, P. J. (2021) · Springer eBooks · doi:10.1007/978-3-030-21573-6_6075-1
Biomarkers of Cardiovascular Disorders
Jain, K. K. (2017) · Springer eBooks · doi:10.1007/978-1-4939-7431-3_15
Lipoprotein(a): An Independent Risk factor of Cardiovascular Disease
Karmakar, P., Farzana, T., Jahan, I., & Haque, M. F. (2022) · Central Medical College Journal · doi:10.3329/cemecj.v5i1.60206
Lipoprotein(a)
Langsted, A., & Nordestgaard, B. G. (2022) · Contemporary cardiology · doi:10.1007/978-3-030-98824-1_16
A cross-sectional study to assess proteinuria and lipoprotein (a) levels in chronic kidney disease
Radhakrishnan, S., Indirajith, V., Chandran, P., Subramanyam, G., Ramu, M., Kandhi, S., & Sasikala, P. M. (2022) · EUREKA Health Sciences · doi:10.21303/2504-5679.2022.002567
Lipoprotein(a) and Calcific Aortic Valve Stenosis
Kosmas, C. E., Silverio, D., Sourlas, A., Campos, F. N., Montan, P. D., & Guzman, E. (2019) · EMJ Cardiology · doi:10.33590/emjcardiol/10310024
Relationship between Lipoprotein(a) and Lung Function assessed in Community-Dwelling Older Adults: Longitudinal and Cross-Sectional AnalysesPreprint
Song, C. K., Keller, T., Regitz‐Zagrosek, V., Steinhagen‐Thiessen, E., Buchmann, N., & Demuth, I. (2023) · Research Square · doi:10.21203/rs.3.rs-2498798/v1
The Role of Lp(a) in Atherosclerosis: An Overview
Matveyenko, A., Pavlyha, M., & Reyes‐Soffer, G. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-24575-6_9
Contemporary Aspects of Lp(a) Metabolism and Therapies Based on Tracer Kinetic Studies in Humans
Chan, D. C., Pang, J., & Watts, G. F. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-24575-6_5
Lp(a) Metabolism
Millar, J. S., & Rader, D. J. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-24575-6_4
Role of Proprotein Convertase Subtilisin Kexin Type 9 in Lipoprotein(a) Metabolism
Gallo, A., Chemello, K., Techer, R., Jaafar, A. K., & Lambert, G. C. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-24575-6_6
Measurement of Lipoprotein(a) in the Clinical Laboratory
SULLIVAN, D. R., Woolnough, C. A., Perera, N., Ramanathan, J., & Badrick, T. C. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-24575-6_18
Elevated Lp(a): Why Should I Test For It, If I Cannot Treat It? A Patient’s Perspective
Tremulis, S. R. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-24575-6_24
60 Years of Lp(a) Research: From Ouchterlonys Double Diffusion to Copy Number Variation and a Significant Risk Factor for CHD
Utermann, G. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-24575-6_1
Self-citation
Lipoprotein(a) in Cardiovascular Risk Assessment
Boffa, M. B., Koschinsky, M. L., & Marcovina, S. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00005-4
Familial Hypercholesterolaemia: Detection, diagnostic issues and collaboration between lipid clinics and general practice
Hedegaard, B. S. (2023) · VBN Forskningsportal (Aalborg Universitet) · doi:10.54337/aau539425604
Análisis clínico-epidemiológico de pacientes con lipoproteína(a) elevada en un hospital de tercer nivel
de Prada, M. G., Segovia, R. C., Martínez, M. D. C., Hidalgo, N. V., López, M. B. S., & Echevarría, A. B. (2023) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2023.12.001
The influence of lipoproteina(a) on cardio-vascular diseases
Maj-Dziedzic, M., Brzozowska, A., Sikora, M., Zarzycka, M., Plewniok, I., Dubiel, J., Maj, A., Śmietana, G., Warno, M., & Kozik, W. (2024) · Journal of Education Health and Sport · doi:10.12775/jehs.2024.54.013
Lipoprotein(a): A Review of Risk Factors, Measurements, and Novel Treatment Modalities
Karp, A., Jacobs, M. M., Barris, B., Labkowsky, A., & Frishman, W. H. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000667
Espoirs et place prochaine potentielle des inhibiteurs de la Lp(a)
Guédon, A. F., Ghrenassia, E., Cohen, A. A., & Boccara, F. (2024) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/j.amcp.2024.01.003
Distribution characteristics of Lipoprotein (a) and non-genetic factors in Chinese Han populationPreprint
Ma, C., Gao, L., Que, Y., Zhao, L., Li, T., & Xu, G. (2024) · Research Square · doi:10.21203/rs.3.rs-4154807/v1
Navigating Lp(a) Measurement Challenges: From Guidelines to Laboratory Perspectives
Parchwani, D. N., Singh, R., & Katoch, C. D. S. (2024) · doi:10.62772/apfcb-news.2024.1.2
Lipoprotein(a) and Lung Function Are Associated in Older Adults: Longitudinal and Cross-Sectional Analyses
Song, C. K., Ohlei, O., Keller, T., Regitz‐Zagrosek, V., Toepfer, S., Steinhagen‐Thiessen, E., Bertram, L., Buchmann, N., & Demuth, I. (2024) · Biomedicines · doi:10.3390/biomedicines12071502 · Cited by 1
Ancestry specific distribution of LPA Kringle IV-Type-2 genetic variants highlight associations to apo(a) copy number, glucose, and hypertensionPreprint
Li, Y., Kronenberg, F., Coassin, S., Vardarajan, B. N., & Reyes‐Soffer, G. (2024) · medRxiv · doi:10.1101/2024.07.09.24310176
Self-citation
Advantages of using Genetically Elevated Lipoprotein(a) Levels in Predicting 5-Year Major Adverse Cardiovascular Events Relating to Coronary Artery Disease in Women
Shek, A. B., Alieva, R. B., Abdullaev, A. A., Fozilov, K. G., Hoshimov, S. U., Абдуллаева, Г. Ж., Zakirova, D. V., Курбанова, Р., Kan, L. E., & Kim, A. R. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2508308
Lp(a). Lo que sabemos, lo que desconocemos y lo que esperamos
Moyá-Amengual, A., & Serrano-Cumplido, A. (2025) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2025.102451
Aspectos fundamentales en la solicitud y determinación de la lipoproteína(a) en el laboratorio clínico
Velilla, T. A., Fernández‐Prendes, C., Amigó, N., Calmarza, P., Anguila, S. C., Estébanez, B. C., Castro, M. J. C., Ceacero-Marín, D., Martínez, I. G., Palencia, M. M., et al. (2025) · Advances in Laboratory Medicine / Avances en Medicina de Laboratorio · doi:10.1515/almed-2024-0090
Bibliometric analysis of treatment modalities in calcific aortic valve stenosis
Yang, H., Yang, Y.-J., Wang, Z., & Tang, L. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1431311
Deciphering Acute Coronary Syndromes Pathobiology Through Proteomics
Nieddu, G., Formato, M., & Lepedda, A. J. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12050188
Clinical Characteristics and Prognosis Analysis of Elderly Patients with Acute Myocardial Infarction Complicated by Multiple Diseases
王, 亚. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.1551464
Therapeutic lowering of lipoprotein(a): implications for improving outcomes in patients with peripheral arterial disease
Nicholls, S. J. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000001002 · Cited by 2
Lipoprotein(a) levels in Irish subjects from a specialised lipid centre
Tustiu, I., Ensar, D., O’Keeffe, A., Begley, E., Boran, G. P., Armstrong, R. L., & Maher, V. M. G. (2025) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-025-04003-5
Relación entre isoformas de apolipoproteína(a) y niveles de lipoproteína(a) en pacientes con síndrome coronario agudo
Fernández-Olmo, R., Mariscal, J. L., Ruano, A. G., Cordero, A., Castillo-Casas, J. M., & Franco, D. (2025) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2025.500870
Lipoprotein(a) Knowledge, Awareness and Assessment among Clinicians in Saudi Arabia: A Nationwide Survey
Jawi, M., Algethami, M. R., Alshahrani, N. Z., Daghistani, H., Almoghrabi, Y. M., Noorelahi, Y., Tawati, D., Algahtani, R. M., & Awan, Z. A. (2025) · Journal of Advanced Trends in Medical Research · doi:10.4103/atmr.atmr_92_25
Additional file 2 of Differential effects of bariatric surgery and lifestyle interventions on plasma levels of Lp(a) and fatty acids
Berk, K. A., Borgeraas, H., Narverud, I., Mulder, M. T., Øyri, L. K. L., Verhoeven, A. J. M., Småstuen, M. C., Bogsrud, M. P., Omland, T., Hertel, J. K., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22606736
Additional file 1 of Differential effects of bariatric surgery and lifestyle interventions on plasma levels of Lp(a) and fatty acids
Berk, K. A., Borgeraas, H., Narverud, I., Mulder, M. T., Øyri, L. K. L., Verhoeven, A. J. M., Småstuen, M. C., Bogsrud, M. P., Omland, T., Hertel, J. K., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22606733
Structure-guided dissection of the genetic variations within human LPA locus and its role in the development of cardiovascular diseases
Antipenko, I. D., Stepanova, A., Shkurnikov, M. Y., Jeiran, K., Baranova, A., & Tonevitsky, A. (2025) · Progress in Lipid Research · doi:10.1016/j.plipres.2025.101375 · Cited by 1
Relationship between apolipoprotein(a) isoforms and lipoprotein(a) levels in patients with acute coronary syndrome
Fernández-Olmo, R., Mariscal, J. L., Ruano, A. G., Cordero, A., Castillo-Casas, J. M., & Franco, D. (2026) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2026.500870
Recent advances in understanding the spectrum of genetic determinants of lipoprotein(a) levels
Stefan, C. (2026) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000001030
Cytosine base editing of LPA in transgenic mice averts large deletions
Chuecos, M. A., Park, S. H., Bhakta, M., Too-Chiobi, U., Betancourth, D., Cao, M., Giorgi, M. D., Walkey, C. J., Tiwari, A., Godin, B., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.02.049 · Cited by 1
Unraveling Emerging Data on Lipoprotein(a)-Driven Cardiovascular Disease via Multiomics: A Review
Vörös, S., Barnes, M. R., Watson, D., Boatwright, W., Lozama, A., Yates, D. P., Narula, J., & Marcovina, S. (2026) · Global Heart · doi:10.5334/gh.1540
Assessing Long-Term Stability of Lipoprotein(a) in Frozen Blood Plasma Samples: A 14-Year Analysis from The Irish Longitudinal Study on Ageing (TILDA)
Connolly, E., McLoughlin, S., O’Halloran, A. M., Hever, A. M., Nautiyal, K., McCormack, M., Crowley, V., & Kenny, R. A. (2026) · HRB Open Research · doi:10.12688/hrbopenres.14357.1
Apolipoprotein(a) inhibits hepatitis C virus through interaction with infectious particles
de Oliveira, C. G. (2016) · theses.fr (ABES) · doi:10.70675/7edc121bzc24dz4105za741z379a659aa834
Approches biochimique, épidémiologique et clinique du métabolisme intégré de la Lipoprotéine (a)
Blanchard, V. (2020) · theses.fr (ABES) · doi:10.70675/3ce7e0fdzecbaz4b18zaf08z34fb33c163ff
Serum Lipoprotein (a) Levels in Patients with Ischemic Stroke
Job, P. T., Sobhakumari, T., & Iype, T. (2026) · International Journal of Health Sciences and Research · doi:10.52403/ijhsr.20260402
Population specific risk thresholds for lipoprotein(a): implications from angiographic data in Central Asia
Mussagaliyeva, A., Tuleutayev, R., Жангелова, Ш. Б., Kapsultanova, D. A., Akhmentayeva, D., ЖАНУЗАК, А. А., Altybayeva, S., & Rakisheva, A. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1749546
Lipoprotein(a) concentration, kringle IV-2 repeat copy number, and myocardial infarction risk in Chinese populations: insights from the INTERHEART China study
Jiang, J., Ma, X., Wei, Y., Su, B., Liu, X., Xiao, Y., Gu, Y., Wang, Z., Luo, D., Gao, H., et al. (2026) · Lipids in Health and Disease · doi:10.1186/s12944-026-02929-y
Lipoprotein(a) cascade screening in coronary artery disease
Littmann, K., Hogling, D. E., Suhel, M., Juhlin, K., Kara, P., Bottai, M., Svedberg, N., Nordenskjöld, A. M., Ekström, M., Mellbin, L., et al. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120759

Authors: Kronenberg, F., & Utermann, G.
Affiliations: Innsbruck Medical University (AT)
Corresponding author: Utermann, G.
ORCID: Kronenberg, F.
Venue: Journal of Internal Medicine
Publisher: Wiley
Published: 2012-11-12
Volume: 273
Issue: 1
Pages: 6-30
ISSN: 0954-6820 (ISSN-L)
1365-2796
DOI: 10.1111/j.1365-2796.2012.02592.x
OpenAlex: W1988877980
Cited by: 521
References: 203
Citations by year: 2026: 40 · 2025: 38 · 2024: 39 · 2023: 41 · 2022: 45 · 2021: 42 · 2020: 36 · 2019: 48 · 2018: 35 · 2017: 36 · 2016: 42 · 2015: 38 · 2014: 20 · 2013: 17 · 2012: 2
FWCI: 4.75
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Journal of Internal Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: Austrian Science Fund
Oesterreichische Nationalbank
Standortagentur Tirol
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
Keywords: lipoprotein(a), LPA gene, coronary heart disease risk, genetic risk factors, Mendelian randomization, apheresis, cardiovascular risk reduction
MeSH terms: Alleles, Coronary Artery Disease, DNA, Gene Frequency, Humans, Polymorphism, Genetic, Lipoprotein(a), Genetic Predisposition to Disease, Mendelian Randomization Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Lipoprotein(a): resurrected by genetics

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks